Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > 6 Fold Dilution To Chase After COVID-19. End Of Story.

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Jul 06, 2021 9:24am

119 Views

Post# 33498221

RE:6 Fold Dilution To Chase After COVID-19. End Of Story.

I don't mean to question your understanding of the human trial methodology but ,

hypothetically if you're entire company's life is waiting on a chronic cough trial and the trial experiences something negative, would you end the trial? Would you finish a trial that no one will run? Or would you stop talking about it and move on?

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland